NUZ - Neurizon Therapeutics

Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed

• Further testing demonstrates Monepantel (MPL) and monepantel sulfone (MPLS) reduce SARS-CoV-2, the causative agent of COVID-19.
• Experimental results to date include repeat studies in VERO cells by two independent laboratories and evaluation of SARS-CoV-2 anti-viral activity in human Calu-3 cells.
• MPL and MPLS have reduced virus burden regardless of laboratory, cell type or timing of treatment (prior or post-infection).
• Preparations for a Phase 1 clinical trial in humans in progress

..... BUT down 25%, because
....[after] granting the right to negotiate an exclusive worldwide royalty bearing commercial licence to use PharmAust's intellectual property in the field of treatment of cancer in animals. PharmAust announces that on Tuesday morning 8 September 2020 it received an email from Elanco stating that the Option will not be exercised.

One of Tony Locantro's hit or miss cy 2020 specials. Mostly hits lately. Ten picks for 2020, PAA one, picked at 10c start of year, although his clents have been in well before that.

No posts for almost three years. Nothing to post about though until Dec 23 when price started to rally.
This little bio-tech is not in my trading universe. Demand since Dec23 has been solid.

Price action during the Placement and SPP.

On October 15th, 2024, PharmAust Limited (PAA) changed its name and ASX code to Neurizon Therapeutics Limited (NUZ).

Neurizon Therapeutics (ASX : NUZ) has signed an exclusive global licensing agreement with Elanco Animal Health, granting Neurizon access to Elanco’s intellectual property and extensive preclinical and manufacturing data for Monepantel — the active pharmaceutical ingredient in Neurizon’s lead therapy, NUZ-001.

The deal significantly accelerates Neurizon’s regulatory and commercial pathway for treating ALS and other neurodegenerative diseases, while reducing development costs. Under the agreement, Neurizon will make a nominal upfront payment, pay regulatory and commercialisation milestones totalling up to US$80m, and provide tiered single-digit royalties on future global net sales. A long-term supply agreement for GMP-compliant Monepantel is also being negotiated, expected to be finalised in H2 CY2025.

$75 million MC